Page last updated: 2024-12-06
bmy 25067
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
N-7-(2-(nitrophenyldithio)ethyl)mitomycin C: better antitumor activity than mitomycin C [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
BMY-25067 : An organic disulfide that is mitomycin C in which the amino group at position 7 is replaced by a {2-[(4-nitrophenyl)disulfanyl]ethyl}amino group. It is a derivative of mitomycin C with activity against a range of tumour cell lines and xenografts. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 56855 |
| CHEBI ID | 195316 |
| MeSH ID | M0155461 |
Synonyms (16)
| Synonym |
|---|
| bmy-25067 |
| bms-181174 |
| bmy 25067 |
| CHEBI:195316 |
| [(1as,8s,8ar,8bs)-8a-methoxy-5-methyl-6-({2-[(4-nitrophenyl)disulfanyl]ethyl}amino)-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate |
| bmy25067 |
| n-7-(2-(nitrophenyldithio)ethyl)mitomycin c |
| 95056-36-3 |
| bms 181174 |
| unii-27o4qkt84g |
| azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-6-((2-((4-nitrophenyl)dithio)ethyl)amino)-, (1as-(1aalpha,8beta,8aalpha,8balpha))- |
| 27o4qkt84g , |
| DTXSID90241743 |
| [(4s,6s,7r,8s)-7-methoxy-12-methyl-11-[2-[(4-nitrophenyl)disulfanyl]ethylamino]-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate |
| (1as,8s,8ar,8bs)-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-6-((2-((4-nitrophenyl)dithio)ethyl)amino)azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione |
| azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-6-((2-((4-nitrophenyl)dithio)ethyl)amino)-, (1as,8s,8ar,8bs)- |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " BMS-181174 was more toxic to all five cell lines in air than in hypoxia; in contrast, MC is more toxic in hypoxia." | ( Cytotoxicity of BMS-181174. Effects of hypoxia, dicoumarol, and repair deficits. Kelley, M; Kemple, B; Rockwell, S, 1995) | 0.29 |
| " Specifically, T-lineage cells show a high degree of resistance to the toxic effects of exposure to chemotherapeutic drugs, whereas B-lineage cells show a high degree of sensitivity." | ( Involvement of gene-specific DNA damage and apoptosis in the differential toxicity of mitomycin C analogs towards B-lineage versus T-lineage lymphoma cells. Bloom, SE; Muscarella, DE, 1997) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (2)
| Class | Description |
|---|---|
| C-nitro compound | A nitro compound having the nitro group (-NO2) attached to a carbon atom. |
| organic disulfide | Compounds of structure RSSR in which R and R' are organic groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (21)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 18 (85.71) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (9.52%) | 5.53% |
| Reviews | 2 (9.52%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (80.95%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||